Sunshine Biopharma Inc (NASDAQ:SBFM) — Market Cap & Net Worth
Market Cap & Net Worth: Sunshine Biopharma Inc (SBFM)
Sunshine Biopharma Inc (NASDAQ:SBFM) has a market capitalization of $5.18 Million ($5.18 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28306 globally and #5577 in its home market, demonstrating a 6.58% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sunshine Biopharma Inc's stock price $1.06 by its total outstanding shares 4905945 (4.91 Million). Analyse how efficiently does Sunshine Biopharma Inc generate cash to see how efficiently the company converts income to cash.
Sunshine Biopharma Inc Market Cap History: 2015 to 2026
Sunshine Biopharma Inc's market capitalization history from 2015 to 2026. Data shows change from $4.91 Trillion to $5.18 Million (-72.90% CAGR).
Index Memberships
Sunshine Biopharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #835 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2680 of 3165 |
Weight: Sunshine Biopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sunshine Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sunshine Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.42x
Sunshine Biopharma Inc's market cap is 0.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.91 Trillion | $1.71K | -$1.65 Million | 2872333137.89x | N/A |
| 2018 | $627.96 Billion | $447.20K | -$2.16 Million | 1404206.08x | N/A |
| 2019 | $17.66 Billion | $21.12K | -$1.66 Million | 836201.03x | N/A |
| 2020 | $30.81 Billion | $71.41K | -$2.78 Million | 431442.86x | N/A |
| 2021 | $114.70 Billion | $228.43K | -$12.44 Million | 502136.33x | N/A |
| 2022 | $6.28 Billion | $4.35 Million | -$26.74 Million | 1444.92x | N/A |
| 2023 | $2.66 Billion | $24.09 Million | -$4.51 Million | 110.57x | N/A |
| 2024 | $14.72 Million | $34.87 Million | -$5.13 Million | 0.42x | N/A |
Competitor Companies of SBFM by Market Capitalization
Companies near Sunshine Biopharma Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Sunshine Biopharma Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Sunshine Biopharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Sunshine Biopharma Inc's market cap moved from $4.91 Trillion to $ 5.18 Million, with a yearly change of -72.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.18 Million | -14.23% |
| 2025 | $6.03 Million | -59.00% |
| 2024 | $14.72 Million | -99.45% |
| 2023 | $2.66 Billion | -57.58% |
| 2022 | $6.28 Billion | -94.53% |
| 2021 | $114.70 Billion | +272.29% |
| 2020 | $30.81 Billion | +74.44% |
| 2019 | $17.66 Billion | -97.19% |
| 2018 | $627.96 Billion | -87.20% |
| 2017 | $4.91 Trillion | +56.25% |
| 2016 | $3.14 Trillion | -36.00% |
| 2015 | $4.91 Trillion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Sunshine Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.18 Million USD |
| MoneyControl | $5.18 Million USD |
| MarketWatch | $5.18 Million USD |
| marketcap.company | $5.18 Million USD |
| Reuters | $5.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor … Read more